Reported Earlier, MannKind's Inhaled Insulin Afrezza Shows Results in 17-Week Study
Portfolio Pulse from Benzinga Newsdesk
MannKind Corporation (NASDAQ:MNKD) announced positive 17-week results from the INHALE-3 study, a Phase 4 U.S. clinical trial evaluating Afrezza® (inhaled insulin) vs. usual care. The study met its primary efficacy endpoint, showing non-inferior changes in HbA1c and better glycemic target achievement in the inhaled insulin group.
June 24, 2024 | 7:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MannKind Corporation's Afrezza® showed positive results in a 17-week Phase 4 study, meeting primary efficacy endpoints and achieving better glycemic targets compared to usual care.
The positive results from the INHALE-3 study indicate that Afrezza® is effective in managing diabetes, which could lead to increased adoption and sales. This is likely to have a positive short-term impact on MNKD's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100